NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...

Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations. Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus ...

First-line aumolertinib plus platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib alone in certain patients with epidermal growth factor ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Hematoxylin and eosin staining revealed poorly differentiated carcinoma with round cells and rhabdoid morphology (A, 100×). Positive expression of CK5/6 (B, 100×) and CK7 (C, 100×). Suggestive SMARCA4 ...